Alembic Pharmaceuticals shares in focus after USFDA nod for key hypertension drug
Alembic Pharmaceuticals will be in focus after securing final USFDA approval for Diltiazem Hydrochloride Tablets, a widely used treatment for high blood pressure and angina. The drug is deemed therapeutically equivalent to Bausch Healths Cardizem. With this approval, Alembics total ANDA count rises to 230. The stock closed at Rs 904.20 on Friday, down 14% so far in 2025.
Alembic Pharmaceuticals will be in focus after securing final USFDA approval for Diltiazem Hydrochloride Tablets, a widely used treatment for high blood pressure and angina. The drug is deemed therapeutically equivalent to Bausch Healths Cardizem. With this approval, Alembics total ANDA count rises to 230. The stock closed at Rs 904.20 on Friday, down 14% so far in 2025.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
